These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782 [TBL] [Abstract][Full Text] [Related]
29. The effect of dopamine antagonists in spontaneous and tardive dyskinesia. Fog R Psychopharmacology Suppl; 1985; 2():118-21. PubMed ID: 2860655 [TBL] [Abstract][Full Text] [Related]
33. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia. Malik P; Andersen MB; Peacock L Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939 [TBL] [Abstract][Full Text] [Related]
34. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. Meyer JM CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943 [TBL] [Abstract][Full Text] [Related]
35. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544 [TBL] [Abstract][Full Text] [Related]